Catalent vs WuXi Biologics: CDMO Comparison
How does Catalent compare to WuXi Biologics?
As of Oct 2026, Catalent: 24 FDA inspections (including 7 NAI, 15 VAI and 2 OAI), 1 FDA warning letter, 39 EMA/MHRA GMP certificates. Signal Score 76.1. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Catalent and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (24 vs 1) — a deeper regulatory paper trail.
- WuXi Biologics carries a cleaner inspection mix — no OAI classifications versus 2 for Catalent.
- Catalent has 1 FDA warning letter on record; WuXi Biologics has none.
- Catalent has materially broader EMA GMP coverage (21 active certificates vs 3) — stronger EU footprint.
- Catalent has stronger MHRA / UK coverage (18 compliant certificates vs 1).
Across the cross-modality scorecard, WuXi Biologics carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Catalent vs WuXi Biologics
How does Catalent compare to WuXi Biologics?
On CDMO Signal's composite Signal Score, Catalent is 76/100 and WuXi Biologics is 83/100; Catalent has 24 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 39 active EMA+MHRA certificates for Catalent vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Catalent or WuXi Biologics?
Catalent has 24 FDA inspections on record (NAI 7 / VAI 15 / OAI 2) and 1 warning letter. WuXi Biologics has 1 FDA inspection on record (NAI 0 / VAI 1 / OAI 0) and 0 warning letters.
How do Catalent and WuXi Biologics compare on European GMP coverage?
Catalent holds 21 active EMA GMP certificates and 18 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Catalent carries a Signal Score of 76/100 and WuXi Biologics carries 83/100 — a small lead for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →